Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2014. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMR) under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to dividend reinvestment.
- Transaction Price: $53.007 per American Depositary Share (ADS).
- Dividend Payment Date: April 10, 2014.
Material Changes
The filing details increases in ADS holdings for specific individuals following the reinvestment of dividends:
- Mrs. D P Connelly: Acquired 45.263 ADSs (personal contribution) and 33.354 ADSs (company matching contribution).
- Mr. W C Louv: Acquired 33.140 ADSs (personal contribution).
These transactions relate to bonuses from 2010, 2011, and 2012 on a post-tax basis. Notional dividends under the matching element will vest based on the percentage of holdings remaining after the relevant measurement period.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the standard disclosure of the bonus plan mechanics.
Investor Verification Points
- Verify the vesting schedule and measurement periods for the 2010, 2011, and 2012 deferred bonuses.
- Confirm the total number of ADSs held by Mrs. D P Connelly and Mr. W C Louv post-transaction.
- Review the full terms of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan regarding matching contributions.